HealthLeaders Media May 16, 2022
Laura Beerman

One Michigan plan is bringing predictive power to patient drug treatment.

As the social determinants of health grab healthcare’s spotlight, the genetic determinants of health provide precision medicine benefits that one health plan is banking on.

Blue Care Network, a subsidiary of Blue Cross Blue Shield of Michigan (BCBS-MI), has launched Blue Cross Personalized Medicine, the state’s first pharmacogenomics (PGx) program. PGx is a subset of genomics that uses genetic testing to help predict an individual patient’s response to specific drug therapies.

“Our first priority with the Blue Cross Personalized Medicine program is to ensure that a physician is able to provide the right medication, at the right dose, as early in the process as possible,” stated a BCBS-MI press...

Today's Sponsors

Canton & Company
Curation Health

Today's Sponsors

Oliver Wyman

Today's Sponsor

Canton & Company

Topics: Equity/SDOH, Healthcare System, Insurance, Patient / Consumer, Payer, Pharma / Biotech, Precision Medicine, Provider
Why Oncology Pharmacists Should Be at the Helm of Precision Medicine in Oncology
Precision Medicine: Is Personalized Care Really Here?
Epic, Cerner dive further into precision medicine with new partnerships
Precision medicine: the rifle vs. shotgun approach to cancer treatment
Precision Medicine vs Antibiotic Resistance